系统性红斑狼疮患者骨坏死的预测因素:前瞻性队列研究
该前瞻性队列研究纳入2428例系统性红斑狼疮患者,随访224295人月,观察122例新发骨坏死事件(发生率6.5/1000人年)。多变量分析显示非裔美国人、男性、吸烟、高剂量泼尼松(≥40mg/日)及较早诊断年代增加骨坏死风险,而诊断年龄每增10岁风险降低20%。
要点
- 非裔美国人骨坏死风险是白人的2倍,男性风险增加约80%,吸烟者增加约50%。
- 口服泼尼松最高日剂量≥40mg(即使≤1个月)显著增加骨坏死风险。
- 诊断年龄每增10岁骨坏死风险降低20%,1990年代后诊断者风险降低50%。
核心结论
- 非裔美国人系统性红斑狼疮患者骨坏死风险是白人的2倍。
- 口服泼尼松20-39mg超过1个月,或40mg/日即使仅1个月,是骨坏死最重要的糖皮质激素预测因素。
研究设计与样本
- 前瞻性队列研究,纳入1987年队列启动至2019年10月的2428例系统性红斑狼疮患者,基于224295人月随访。
- 采用合并逻辑回归评估风险因素与骨坏死事件率的关系,并拟合最终多变量模型。
主要发现
- 随访18691人年观察到122例新发骨坏死事件,发生率为6.5/1000人年。
- 多变量分析中,非裔美国人风险是白人的2倍;男性风险增加约80%,吸烟者增加约50%。
- 诊断年龄每增10岁,骨坏死风险降低20%;1990年代后诊断者较之前诊断者风险降低50%。
- 最高日剂量泼尼松≥40mg(即使给药≤1个月)显著增加骨坏死风险。
- 使用脉冲甲泼尼龙或肌注曲安奈德与骨坏死风险增加无关。
关键数值与推荐
- 口服泼尼松20-39mg超过1个月,或40mg/日即使仅1个月,在任何疾病阶段均为骨坏死最重要的糖皮质激素预测因素。
临床怎么用
- 对系统性红斑狼疮患者应评估骨坏死风险,尤其非裔美国人、男性、吸烟者及使用高剂量口服泼尼松者。
- 使用口服泼尼松≥40mg/日即使短期也应警惕骨坏死风险,脉冲甲泼尼龙或肌注曲安奈德未显示增加风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed at determining the predictors of osteonecrosis (ON) in a longitudinal lupus cohort. METHODS: Data were reviewed from the initiation of the cohort in 1987 until October 2019. In total, 2,428 patients were included in the analysis based on 224,295 person-months of follow-up. We used pooled logistic regression to assess the relationship between risk factors and rates of ON events. After identifying a set of variables related to ON incidence, we fit a final multivariable model to identify the most important risk factors for incident ON. RESULTS: In 18,691 person-years of follow-up after cohort entry, 122 incident ON events were observed (rate = 6.5/1,000 person-years). In the multivariable analysis, African American patients were at twice the risk for ON compared to White patients. Male patients and smokers had an increased risk for ON of ~80% and 50% compared to female patients and nonsmokers, respectively. For every 10-year increase in the age at diagnosis, there was a 20% reduced risk for ON. Patients diagnosed after the 1990s had a 50% reduced risk of ON compared to those diagnosed before the 1990s. A highest daily dosage of prednisone of 40 mg or higher, even when administered for a month or less, significantly increased the risk of ON. Use of pulse methylprednisolone or intramuscular triamcinolone was not associated with an increased risk of ON. CONCLUSION: African American patients with systemic lupus erythematosus are at double the risk of experiencing ON compared to White patients. Oral prednisone at 20-39 mg for more than 1 month, or 40 mg daily for even 1 month, at any point in the disease course, remained the most important glucocorticoid predictor of ON.
引用
- Kallas R, Li J, Petri M, et al. Predictors of Osteonecrosis in Systemic Lupus Erythematosus: A Prospective Cohort Study. Arthritis Care Res (Hoboken). 2022. PMID: 33342072. doi:10.1002/acr.24541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。